Results 1 to 10 of about 349 (107)

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis [PDF]

Indian Journal of Endocrinology and Metabolism
No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination ...
Ameya S Joshi, Deep Dutta, Lakshmi Nagendra   +2 more
exaly   +6 more sources

Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials. [PDF]

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Chuhan Shao, Hanmo Lin, Jie Yu, Haiyan Chen, Yaolin Ren, Jing Ren, Yuan Zeng, Yifan Wu, Haoyu Bai, Qian Zhang, Xinhua XiaoNHC Key Laboratory of Endocrinology (Peking Union Medical College Hospital), Diabetes Research Center of Chinese Academy of Medical ...
Yaolin Ren
exaly   +5 more sources

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Background Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
A. B. M. Kamrul‐Hasan, Ibrahim Khalil, Kunal Mahajan, Deep Dutta, Mainak Banerjee, Joseph M. Pappachan   +5 more
doaj   +3 more sources

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials [PDF]

Endocrinology, Diabetes & Metabolism
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
doaj   +3 more sources

Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis [PDF]

BMJ Open
Background Cardiovascular diseases, overweight, type 2 diabetes and chronic kidney disease increase the risk of cardiovascular events.Glucagon-like peptide-1 analogues are recommended by the European Society of Cardiology and the American College of ...
Christian Gluud, Anne Frølich, Ole Mathiesen, Peter Haulund Gæde, Janus C Jakobsen, Helena Dominguez, Pascal Faltermeier, Johanne Juul Petersen, Johannes Grand, Christina Dam Bjerregaard Sillassen, Caroline Barkholt Kamp   +10 more
doaj   +3 more sources

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials [PDF]

BMJ Medicine
Objective To compare the efficacy and safety of glucagon-like peptide 1 (GLP-1) based drug treatments for weight loss in adults with overweight or obesity without diabetes.Design Network meta-analysis of randomised controlled trials.Data sources Embase ...
Jing Zhang, Min Chen, Hao Sun, Yongze Li, Bing Ma, Weiwei Wang, Yanli Cao, Deshi Chen, Linlin Gong, Zihan Liu, Hongying Zha, Shuaibo Du, Wenxin Sun, Qiqiang Guo   +13 more
doaj   +3 more sources

Incretin analogues as cardiovascular agents: a state-of-the-art review [PDF]

Frontiers in Endocrinology
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide have evolved over the past decade from glucose-lowering antidiabetic agents into a cardiovascular ...
Diego Araiza-Garaygordobil, Diego Araiza-Garaygordobil, Jorge Rico-Fontalvo, Jorge Rico-Fontalvo, Betsabe Hernández-Balbuena, Monica Vinay-Coro, Mauricio González-Arias   +6 more
doaj   +3 more sources

Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes [PDF]

Metabolism Open
Introduction: Amylin-pathway therapies represent a novel therapeutic class for obesity and type 2 diabetes, however head-to-head comparative data and long-term outcome predictions remain limited.
Faisal A. Al-Harbi, Ahmed K. Alsaif, Atheer G. Almutairi, Hussam J. Alshehri, Elan A. Aleidan, Ghaida S. Alabdulaaly, Mashael E. Alanazi, Ahmed Y. Azzam   +7 more
doaj   +2 more sources

Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists [PDF]

Pharmaceutics
Both diabetes mellitus (DM) and stroke are major global health challenges with high morbidity and mortality. DM is a major risk factor for stroke, contributing to both increased incidence and worse clinical outcomes.
Maria-Alexandra Paceana, Liliana Mititelu Tartau, Ianis Kevyn Stefan Boboc, Carmen Nicoleta Oancea, Anca Berbecaru-Iovan, Cezar Ilie Foia, Cosmin Gabriel Tartau, Maria Bogdan   +7 more
doaj   +2 more sources

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders [PDF]

Clinical and Molecular Hepatology
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders.
Yun Kyung Cho, Chang Hee Jung
doaj   +2 more sources